KRAS and neoplasm: This prompted us to investigate the effects of tumour-specific KRAS inhibition on the TME in the context of a preclinical model of lung cancer, the 3LL ΔNRAS cell line, a KRAS G12C mutant and NRAS-knockout Lewis lung carcinoma derivative that we have previously shown to be sensitive to KRAS G12C inhibition17.